SRRK icon

Scholar Rock

36.20 USD
-0.83
2.24%
Updated Feb 12, 11:26 AM EST
1 day
-2.24%
5 days
-14.28%
1 month
-15.02%
3 months
35.78%
6 months
281.86%
Year to date
-18.03%
1 year
129.84%
5 years
164.43%
10 years
133.55%
 

About: Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

Employees: 150

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1.29% more ownership

Funds ownership: 106.83% [Q2] → 108.12% (+1.29%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 54

2% less capital invested

Capital invested by funds: $710M [Q2] → $694M (-$16.1M) [Q3]

3% less funds holding

Funds holding: 164 [Q2] → 159 (-5) [Q3]

14% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 29

27% less call options, than puts

Call options by funds: $4.71M | Put options by funds: $6.43M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$45
24%
upside
Avg. target
$47
31%
upside
High target
$50
38%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Andres Maldonado
30% 1-year accuracy
14 / 46 met price target
38%upside
$50
Buy
Maintained
26 Nov 2024
Wedbush
David Nierengarten
40% 1-year accuracy
50 / 125 met price target
30%upside
$47
Outperform
Maintained
25 Nov 2024
Truist Securities
Srikripa Devarakonda
34% 1-year accuracy
12 / 35 met price target
24%upside
$45
Buy
Maintained
25 Nov 2024

Financial journalist opinion

Based on 6 articles about SRRK published over the past 30 days

Neutral
Business Wire
2 days ago
Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its fourth quarter and full year 2024 financial results and provide a business update on Thursday, February 27, 2025, at 8:15am ET. To acce.
Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025
Positive
Seeking Alpha
1 week ago
Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data
Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Apitegromab is being explored in the phase 2 proof-of-concept EMBRAZE study, given alongside GLP-1 drugs to treat patients with obesity; Data from this trial is expected in Q2 of 2025. Positive data from the phase 2 EMBRAZE study would lead to IND of SRK-439 in Q3 of 2025 to target obesity and other cardiometabolic disorders.
Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data
Neutral
Business Wire
2 weeks ago
Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration (FDA) for apitegromab, a muscle-targeted therapy designed and developed to provide clinically meaningfu.
Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)
Neutral
Business Wire
2 weeks ago
Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, announced today that Lisa Wyman has been appointed to the new role of Chief Technical and Quality Officer (CTQO) to support the Company's ongoing growth and evolution to becoming a fully integrated biopharma co.
Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition
Neutral
Business Wire
3 weeks ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 48,000 shares of its common stock to three newly hired employees, consisting of inducement stock options to pu.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Positive
Benzinga
3 weeks ago
Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth
Scholar Rock Holding Corporation SRRK President & CEO Jay Backstrom presented at the J.P. Morgan Healthcare Conference.
Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth
Neutral
Business Wire
1 month ago
Scholar Rock Highlights 2025 Strategic Priorities
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2025. “We are excited about the potential for apitegromab to help those living with SMA as the first and only muscle-targeted ther.
Scholar Rock Highlights 2025 Strategic Priorities
Neutral
Business Wire
1 month ago
Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 9:45 a.m. PT (12:45 p.m. ET). A live webcast of the presentation may be accesse.
Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Neutral
Business Wire
1 month ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 208,800 shares of its common stock to twelve newly hired employees, consisting of inducement stock options to.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Positive
Benzinga
2 months ago
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
On Monday, Biohaven Ltd. BHVN updated the taldefgrobep alfa development programs in Spinal Muscular Atrophy (SMA) and obesity.
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
Charts implemented using Lightweight Charts™